既往SARS-CoV-2感染对COVID-19疫苗接种后结合抗体与中和抗体应答的影响:六项3期临床试验个体水平数据的跨方案分析
该跨方案分析汇总六项COVID-19 3期疫苗试验的个体数据,比较疫苗免疫、自然免疫和混合免疫三层的血清结合抗体浓度与中和抗体ID50滴度,并校正年龄、性别和BMI。结果显示,未感染者的抗体应答通常需第二剂才大幅提升,而既往感染者单剂即可达到或超过未感染者两剂的峰值应答,且群体抗体水平与疫苗效力高度一致。
要点
- 未感染者需两剂疫苗才能产生与保护相关的抗体水平。
- 既往感染者单剂任何平台疫苗即可产生 comparably 高的抗体水平。
- 群体抗体水平与疫苗效力在不同试验和免疫分层间高度一致。
核心结论
- 未感染者需两剂疫苗方案才能提供与针对同源病毒株疾病保护相关的抗体水平。
- 既往SARS-CoV-2感染者单剂任何测试疫苗或平台即可提供 comparably 高的抗体水平。
研究设计与样本
- 六项COVID-19 3期疫苗效力试验的跨方案个体水平数据分析,使用经验证的抗体检测。
- 比较疫苗免疫、自然免疫和混合免疫三层的血清结合抗体浓度与中和抗体ID50滴度,校正年龄、性别和BMI。
主要发现
- 单剂疫苗后抗体水平因试验而异,未感染者通常在第二剂后增幅最大。
- 混合免疫者单剂后抗体倍数升高更明显,单剂应答可比或超过未感染者两剂疫苗的峰值应答。
- 群体抗体水平与疫苗效力在不同试验和免疫分层间高度一致。
临床怎么用
- 对未感染者应完成两剂疫苗方案以产生与保护相关的抗体水平。
- 对既往SARS-CoV-2感染者,单剂任何测试平台疫苗即可产生 comparably 高的抗体水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 Prevention Network (CoVPN) co-conducted six COVID-19 phase 3 vaccine efficacy (VE) trials that featured harmonized immunogenicity analyses using validated antibody assays. These trials enabled a uniquely comprehensive characterization of immunogenicity produced by different vaccine platforms and regimens in individuals with and without prior SARS-CoV-2 acquisition. METHODS: Comparisons of serum binding antibody concentration and serum neutralization antibody ID50 titers were performed across three strata: vaccine immunity (vaccination in SARS-CoV-2-naïve individuals), natural immunity (placebo with prior SARS-CoV-2 acquisition), and hybrid immunity (vaccination after prior SARS-CoV-2 acquisition). We compared immunogenicity across immunity strata for each trial and each dose, adjusting for age, sex assigned at birth, and body mass index. Antibody levels were also examined in relation to VE. RESULTS: Antibody levels in response to a single vaccine dose varied across trials and generally increased most substantially after a second dose in naïve participants. Fold rise in antibody levels after a single dose were more pronounced in participants with hybrid immunity: a single dose of any of the tested vaccine yielded responses comparable to or exceeding the post-dose-two (peak) response of any two-dose vaccine in naïve participants. Population-level antibody levels demonstrated high concordance with VE across trials and immunity strata. CONCLUSIONS: In SARS-CoV-2-naïve individuals, a two-dose vaccine regimen is needed to provide antibody levels correlated with protection against disease caused by the cognate virus strain. In contrast, in individuals with prior SARS-CoV-2 acquisition, a single dose of any of the tested vaccines/platforms (mRNA/protein/vector) provides comparably high antibody levels.
引用
- Hudson A, Borgetti S, Rick AM, et al. Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026. PMID: 41730823. doi:10.1016/j.vaccine.2026.128380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。